| Similar Articles |
|---|
 |
Chemistry World
December 8, 2011
Maria Burke |
Government Launches UK Life Sciences Strategy Prime minister David Cameron has announced a package of measures designed to boost the UK's life sciences industry.   |
Pharmaceutical Executive
December 1, 2011 |
UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity. |
Managed Care
May 2004 |
Biologics Among Fastest Growers Managed care plans and pharmacy benefit managers can benefit from the strong generic presence in the market, but also face challenges relating to biotech drugs. |
Chemistry World
March 2009
James Mitchell Crow |
Editorial: Great debate Are university-based researchers about to receive a huge windfall? Or could blue-skies research - which by its very nature needs a free reign from government funders - become the next victim? |
The Motley Fool
October 9, 2006
Brian Lawler |
The Commandments of Biotech Investing, Part 2 It's a complex field, but it's not impossible for investors to master. The more in-depth your research of a potential biotech investment, and the more you remember to follow these commandments, the better your potential for success will be when investing in this fascinating field. |
Chemistry World
February 2008
Nuala Moran |
The Chemistry of Private Equity Private equity has transformed the chemicals industry, but can it play the same role in high-risk R&D driven companies? |
Chemistry World
June 9, 2009
Sarah Houlton |
New department takes responsibility for UK science The UK government reshuffle has reunited the departments responsible for business and science. |
Chemistry World
April 23, 2013
Emma Stoye |
Invest in research or be left behind, UK academies warn The UK's four national academies have called on the government to increase investment in research over the next decade or risk being overtaken by international competitors. |
Pharmaceutical Executive
December 1, 2013
Peter Young |
2013 Pharma and Biotech Financial Report Big Pharma and biotech continue to need each other. But biotech is feeling slightly more confident as the options for IPOs get better. |
Chemistry World
April 22, 2009
Matt Wilkinson |
Darling budgets for high tech growth Alistair Darling, the UK's Chancellor of the Exchequer, gave a speech which focused heavily on how he wants to produce a 'hi tech Britain that will lead our economic recovery' |
Bio-IT World
October 14, 2004
Robinson & Violino |
Strategic Insights: Global Positioning International Economic Development for biotech companies in search of a better location or international presence, countries in Asia and Europe are offering a host of incentives, including tax credits and reduced red tape. |
Fast Company
February 2009
Elizabeth Svoboda |
Wyeth's Multibillion-dollar Biotech Bet Drugmaker Wyeth bet billions on biotech, transforming its culture and boosting profits. |
Chemistry World
April 2010
Bibiana Campos Seijo |
Editorial: Election science Science is very much on the agenda in the UK, with many a report being launched during the last month. |
The Motley Fool
December 16, 2003
David Nierengarten |
Biotech's Next Phase It's been a great year for biotech, but don't count on a repeat in 2004. Here are some tips for evaluating biotechnology and pharmaceutical stocks. |
Bio-IT World
October 2006
Thomas G. Morr |
Eight Essential Elements for Commercial Success For life sciences companies both young and old, location is one of the critical success factors. With that in mind, here are eight essential considerations for life sciences executives when they are thinking of starting a business or opening a new location. |
The Motley Fool
November 16, 2006
Jim Fink |
The Best ETF for 2007: H&Q Life Sciences Investors H&Q Life Sciences, a health-care fund investing in one of the highest-growth sectors of the U.S. economy, is trading at a discount to NAV. Consequently, it's now primed to be the best-performing ETF for 2007. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
Pharmaceutical Executive
December 1, 2006
Sarah Houlton |
Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines. |
BusinessWeek
November 10, 2003
Arlene Weintraub |
Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
The Motley Fool
May 5, 2004
Brian Gorman |
Albany Molecular Gets Out-Outsourced Albany Molecular Research, provider of chemistry services to biotech and pharmaceutical clients, is suffering from the loss of business to low-cost competitors overseas. |
Chemistry World
March 4, 2013
Andy Extance |
UK considers patent rule change for trials The UK has announced plans to amend aspects of its patent law that may be encouraging pharma companies to run their clinical trials in other countries. |
Knowledge@Wharton
March 26, 2003 |
Health Care Finance Industry Plagued by Lack of Funding, Focus In today's health care finance environment, early financing rounds are harder to fund and the market for initial public financings is dead, with no revival expected anytime soon. |
Bio-IT World
June 15, 2003
Melissa Kruse |
Midwest/South Region Ohio: Outpacing U.S. in Bioscience Growth... Alabama: Sweet Home to Tech Tax Incentives... Kentucky: Investing Multimillions to Breed Bio Business... Minnesota: The 'Right Mix' of Talent and Funding... Tennessee: Pioneering Research Centers... Michigan: Teeming 'Life Sciences Corridor'... etc. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
Pharmaceutical Executive
November 1, 2008
Sarah Houlton |
Cash Flow Woes in EU In Europe, the wildly different attitudes toward healthcare across the different member states make for a complex pharmaceutical marketplace. |
| Knowledge@Wharton |
Encouraging the Development of Drugs for Poor, not Just Rich, Nations The current system rewards research into diseases that afflict rich countries, but creating new medicines for the rest of the world and finding ways to pay for them will demand new partnerships, according to panelists at the recent conference "Pharmaceutical Innovation in a Global Economy." |
Chemistry World
May 2012 |
Biotech's bravura performer Bibiana Campos Seijo talks to scientist, philanthropist and serial entrepreneur Chris Evans, who is credited with having helped create the UK biotechnology industry. |
The Motley Fool
April 5, 2011
Frank Vinluan |
Tranzyme Pharma's Public Offering Raises $48M, but IPO Has Little Bounce Tranzyme Pharma likely had hopes for an opening bounce on the day the drug development company went public, but that ball fell flat. |
Bio-IT World
June 15, 2003
Bob Violino |
Mid-Atlantic/Southeast Region Maryland: Making a Federal Case for Biotechnology... Puerto Rico: Isle of Incentives... Virginia: Planting Needed Seed Capital... North Carolina: Triangulating Biotech Resources... Florida: Shining Resources on Small Biotech Sector |
Chemistry World
August 23, 2012
Simon Campbell |
Protecting patients at all costs A new funding model is urgently required to deliver innovative medicines that meet the medical needs of the 21st century and contribute to economic growth. |
The Motley Fool
June 7, 2007
Brian Lawler |
Are You Ignoring the Most Exciting Stocks? Never considered drug stocks? You're missing some of the market's best investments. |
Chemistry World
June 2009
Lord Drayson |
World-leading research In the current climate - not just the downturn, but the reality of intense global competition - UK research chemists must join forces with business and government to exploit our abundant talent and potential. |
The Motley Fool
September 9, 2004
Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Bio-IT World
April 2006
Samara McCarthy |
Ireland's Biotech Boom How the Emerald Isle has made its name in the life sciences. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
Pharmaceutical Executive
June 1, 2013 |
Country Report: Ireland Ireland has been a pharma industry darling since the 1960s, when a then-newly established IDA targeted the sector as a strategic area for development. Today, the numbers are eye catching. |
Chemistry World
December 17, 2009
Andy Extance |
STFC funding axe bodes ill for UK science The UK Science and Technology Facilities Council has announced a series of program cuts and priority shifts, indicating a direction for British research that some researchers have reacted angrily to. |
| Knowledge@Wharton |
The Benefits Are Mutual in New Wave of Biotech/Pharma Alliances The spat that erupted between pharma giant Bristol-Myers Squibb and biotech firm ImClone Systems over their partnership to develop a new cancer drug put the structure of alliances between discovery research firms and big drug makers under a microscope... |
Chemistry World
March 7, 2008
Peter Mitchell |
Uk Drug Pricing System Scrapped The UK government is scrapping its existing national scheme for controlling drug prices. The system, called the Pharmaceutical price regulation scheme (PPRS), will be replaced by a newly negotiated agreement on 1 September 2008. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
The Motley Fool
February 12, 2007
Brian Lawler |
I Love Drug Stocks This Valentine's Day, leave a special place in your heart for drug stocks. |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. |
Investment Advisor
August 2006 |
S&P Mutual Fund Sector Focus: Health Care Funds Tired and Sluggish Big pharma names dominate most health care funds and these businesses are beset with problems. One of the best longer-term performers in this area, the $561-million Schwab Health Care Fund. |
Chemistry World
June 18, 2008
Ananyo Bhattacharya |
Deal on NHS drugs set to trim pharma profits An agreement between the UK government and the pharmaceutical industry will cut around five per cent off the cost of medicines sold to the National Health Service |
Chemistry World
January 29, 2013
Laura Howes |
Five green chemical feedstock projects launched The UK's Engineering and Physical Sciences Research Council has announced 10.7 million pounds, in combination with 1.1 million pounds from the Biotechnology and Biological Sciences Research Council, to fund five projects to develop new bio-based feedstocks for the chemical industry. |
Pharmaceutical Executive
August 1, 2008
Sarah Houlton |
Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared. |
Chemistry World
September 23, 2010
Anna Lewcock |
UK faces scientific exodus The UK faces a 'significant' risk of researchers abandoning its shores and long-term damage to the science base if proposed funding cuts go ahead |
The Motley Fool
January 28, 2008
Brian Lawler |
A Great Way to Recession-Proof Your Portfolio If you want a recession resistant portfolio, invest in large cap pharmaceuticals. |
